Skip to main content
SpringerLink
Log in

Chemical biology approach for the development of hypoxia inducible factor (HIF) inhibitor LW6 as a potential anticancer agent

  • Review
  • Published:
Archives of Pharmacal Research Aims and scope Submit manuscript

Abstract

Intratumoral hypoxia has long been considered to be a driving force in tumor progression as well as a negative prognostic factor in human cancers. The discovery of hypoxia inducible factors (HIFs), which mediate transcriptional responses to changes in oxygen levels, has renewed enthusiasm for drug discovery and the development of targeted therapies in this field. LW6 represents an important new class of small molecules that inhibit HIF-1; it has been major source for diverse lead compounds including HIF-1α inhibitors. Through a chemical biology approach, LW6-derived chemical probes were successfully utilized for the identification of the direct targeting of a protein in cancer. LW6 provides a valuable platform for the discovery and development of small molecule inhibitors of HIF-1α-dependent tumor progression, metabolic reprogramming, and angiogenesis.

Graphical Abstract

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Scheme 1
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10
Fig. 11

Similar content being viewed by others

References

  • Ban, H.S., K. Shimizu, H. Minegishi, and H. Nakamura. 2010. Identification of HSP60 as a primary target of o-Carboranylphenoxyacetanilide, an HIF-1α inhibitor. Journal of the American Chemical Society 132: 11870–11871.

    Article  CAS  PubMed  Google Scholar 

  • Boovanahalli, S.K., X. Jin, Y. Jin, J.H. Kim, N.T. Dat, Y.S. Hong, J.H. Lee, S.H. Jung, K. Lee, and J.J. Lee. 2007. Synthesis of (aryloxyacetylamino)-isonicotinic/nicotinic acid analogues as potent hypoxia-inducible factor (HIF)-1alpha inhibitors. Bioorganic & Medicinal Chemistry Letters 17: 6305–6310.

    Article  CAS  Google Scholar 

  • Borsi, E., G. Perrone, C. Terragna, M. Martello, A.F. Dico, G. Solaini, A. Baracca, G. Sgarbi, G. Pasquinelli, S. Valente, E. Zamagni, P. Tacchetti, G. Martinelli, and M. Cavo. 2014. Hypoxia inducible factor-1 alpha as a therapeutic target in multiple myeloma. Oncotarget 5: 1779–1792.

    PubMed Central  PubMed  Google Scholar 

  • Bowles, D.W., W.W. Ma, N. Senzer, J.R. Brahmer, A.A. Adjei, M. Davies, A.J. Lazar, A. Vo, S. Peterson, L. Walker, D. Hausman, C.M. Rudin, and A. Jimeno. 2013. A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours. British Journal of Cancer 109: 1085–1092.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Brown, J.M., and W.R. Wilson. 2004. Exploiting tumor hypoxia in cancer treatment. Nature Reviews Cancer 4: 437–447.

    Article  CAS  PubMed  Google Scholar 

  • Chun, Y.S., E.J. Yeo, E. Choi, C.M. Teng, J.M. Bae, M.S. Kim, and J.W. Park. 2001. Inhibitory effect of YC-1 on the hypoxic induction of erythropoietin and vascular endothelial growth factor in Hep3B cells. Biochemical Pharmacology 61: 947–954.

    Article  CAS  PubMed  Google Scholar 

  • Chung, J.Y., F.A. Pasha, S.J. Cho, M. Won, J.J. Lee, and K. Lee. 2009. Pharmacophore-based 3D-QSAR of HIF-1 inhibitors. Archives of Pharmacal Research 32: 317–323.

    Article  CAS  PubMed  Google Scholar 

  • Forsythe, J.A., B.H. Jiang, N.V. Iyer, F. Agani, S.W. Leung, R.D. Koos, and G.L. Semenza. 1996. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Molecular and Cellular Biology 16: 4604–4613.

    PubMed Central  CAS  PubMed  Google Scholar 

  • Ghosh, B., and L.H. Jones. 2014. Target validation using in-cell small molecule clickable imaging probes. MedChemComm 5: 247–254.

    Article  CAS  Google Scholar 

  • Giaccia, A., B.G. Siim, and R.S. Johnson. 2003. HIF-1 as a target for drug development. Nature Reviews Drug Discovery 2: 803–811.

    Article  CAS  PubMed  Google Scholar 

  • Gleadle, J.M., and P.J. Ratcliffe. 1997. Induction of hypoxia-inducible factor-1, erythropoietin, vascular endothelial growth factor, and glucose transporter-1 by hypoxia: evidence against a regulatory role for Src kinase. Blood 89: 503–509.

    CAS  PubMed  Google Scholar 

  • Goward, C.R., and D.J. Nicholls. 1994. Malate dehydrogenase: A model for structure, evolution, and catalysis. Protein Science 3: 1883–1888.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Greenberger, L.M., I.D. Horak, D. Filpula, P. Sapra, M. Westergaard, H.F. Frydenlund, C. Albaek, H. Schrøder, and H. Ørum. 2008. A RNA antagonist of hypoxia-inducible factor-1alpha. EZN-2968, inhibits tumor cell growth. Molecular Cancer Therapeutics 7: 3598–3608.

    Article  CAS  PubMed  Google Scholar 

  • Guo, N., and Z. Peng. 2013. MG132, a proteasome inhibitor, induces apoptosis in tumor cells. Asia‐Pacific Journal of Clinical Oncology 9: 6–11.

    PubMed  Google Scholar 

  • Han, S.Y., and S.H. Kim. 2007. Introduction to chemical proteomics for drug discovery and development. Archiv der Pharmazie 340: 169–177. (Weinheim).

    Article  CAS  PubMed  Google Scholar 

  • Hanahan, D., and J. Folkman. 1996. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353–364.

    Article  CAS  PubMed  Google Scholar 

  • Harris, A.L. 2002. Hypoxia—A key regulatory factor in tumor growth. Nature Reviews Cancer 2: 38–47.

    Article  CAS  PubMed  Google Scholar 

  • Ihle, N.T., R. Williams, S. Chow, W. Chew, M.I. Berggren, G. Paine-Murrieta, D.J. Minion, R.J. Halter, P. Wipf, R. Abraham, L. Kirkpatrick, and G. Powis. 2004. Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling. Molecular Cancer Therapeutics 3: 763–772.

    CAS  PubMed  Google Scholar 

  • Jeffery, D.A., and M. Bogyo. 2004. Chemical proteomics and its application to drug discovery. Drug Discovery Today 9: S19–S26.

    PubMed  Google Scholar 

  • Kaur, N., Y. Xia, Y. Jin, N.T. Dat, K. Gajulapati, Y. Choi, Y.S. Hong, J.J. Lee, and K. Lee. 2009. The first total synthesis of Moracin O and Moracin P, and establishment of the absolute configuration of Moracin O. Chemical Communications 14: 1879–1881.

    Article  PubMed  Google Scholar 

  • Kim, B.S., K. Lee, H.J. Jung, D. Bhattarai, and H.J. Kwon. 2015. HIF-1α suppressing small molecule, LW6, inhibits cancer cell growth by binding to calcineurin b homologous protein 1. Biochemical and Biophysical Research Communications 458: 14–20.

    Article  CAS  PubMed  Google Scholar 

  • Kotzyba-Hibert, F., I. Kapfer, and M. Goeldner. 1995. Recent trends in photoaffinity labeling. Angewandte Chemie (International Edition in English) 34: 1296–1312.

    Article  CAS  Google Scholar 

  • Lee, K., J.H. Lee, S.K. Boovanahalli, Y. Jin, M. Lee, X. Jin, J.H. Kim, Y.S. Hong, and J.J. Lee. 2007. (Aryloxyacetylamino)benzoic acid analogues: A new class of hypoxia-inducible factor-1 inhibitors. Journal of Medicinal Chemistry 50: 1675–1684.

    Article  CAS  PubMed  Google Scholar 

  • Lee, K., J.E. Kang, S.K. Park, Y.L. Jin, K.S. Chung, H.M. Kim, K. Lee, M.R. Kang, M.K. Lee, K.B. Song, E.G. Yang, J.J. Lee, and M.S. Won. 2010. LW6, a novel HIF-1 inhibitor, promotes proteasomal degradation of HIF-1alpha via upregulation of VHL in a colon cancer cell line. Biochemical Pharmacology 80: 982–989.

    Article  CAS  PubMed  Google Scholar 

  • Lee, K., H.S. Ban, R. Naik, Y.S. Hong, S. Son, B.K. Kim, Y. Xia, K.B. Song, H.S. Lee, and M. Won. 2013. Identification of malate dehydrogenase 2 as a target protein of the HIF-1 inhibitor LW6 using chemical probes. Angewandte Chemie (International Edition in English) 52: 10286–10289.

    Article  CAS  Google Scholar 

  • Li, S.H., D.H. Shin, Y.S. Chun, M.K. Lee, M.S. Kim, and J.W. Park. 2008. A novel mode of action of YC-1 in HIF inhibition: Stimulation of FIH-dependent p300 dissociation from HIF-1α. Molecular Cancer Therapeutics 7: 3729–3738.

    Article  CAS  PubMed  Google Scholar 

  • Naik, R., M. Won, B.K. Kim, Y. Xia, H.K. Choi, G. Jin, Y. Jung, H.M. Kim, and K. Lee. 2012. Synthesis and structure − activity relationship of (E)-phenoxyacrylic amide derivatives as hypoxia-inducible factor (HIF) 1α inhibitors. Journal of Medicinal Chemistry 55: 10564–10571.

    Article  CAS  PubMed  Google Scholar 

  • Naik, R., M. Won, H.S. Ban, D. Bhattarai, X. Xu, Y. Eo, Y.S. Hong, S. Singh, Y. Choi, H.C. Ahn, and K. Lee. 2014. Synthesis and structure–activity relationship study of chemical probes as hypoxia induced factor-1α/malate dehydrogenase 2 inhibitors. Journal of Medicinal Chemistry 57: 9522–9538.

    Article  CAS  PubMed  Google Scholar 

  • Park, J.W., Y.G. Chun, K. Bair, and S. Cho. 2007. Compound for treating angiogenesis. US Patent No. 7,226,941 B2. Washington, DC: U.S. Patent and Trademark Office.

  • Park, J., S. Oh, and S.B. Park. 2012. Discovery and target identification of an antiproliferative agent in live cells using fluorescence difference in two-dimensional gel electrophoresis. Angewandte Chemie (International Edition in English) 51: 5447–5451.

    Article  CAS  Google Scholar 

  • Persidis, A. 1998. Signal transduction as a drug-discovery platform. Nature Biotechnology 16: 1082–1083.

    Article  CAS  PubMed  Google Scholar 

  • Puppo, M., F. Battaglia, C. Ottaviano, S. Delfino, D. Ribatti, L. Varesio, and M.C. Bosco. 2008. Topotecan inhibits vascular endothelial growth factor production and angiogenic activity induced by hypoxia in human neuroblastoma by targeting hypoxia-inducible factor-1alpha and -2alpha. Molecular Cancer Therapeutics 7: 1974–1984.

    Article  CAS  PubMed  Google Scholar 

  • Rapisarda, A., B. Uranchimeg, D.A. Scudiero, M. Selby, E.A. Sausville, R.H. Shoemaker, and G. Melillo. 2002. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Research 62: 4316–4324.

    CAS  PubMed  Google Scholar 

  • Semenza, G.L. 1999. Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annual Review of Cell and Developmental Biology 15: 551–578.

    Article  CAS  PubMed  Google Scholar 

  • Semenza, G.L. 2003. Targeting HIF-1 for cancer therapy. Nature Reviews Cancer 3: 721–732.

    Article  CAS  PubMed  Google Scholar 

  • Shimizu, K., M. Maruyama, Y. Yasui, H. Minegishi, H.S. Ban, and H. Nakamura. 2010. Boron-containing phenoxyacetanilide derivatives as hypoxia-inducible factor (HIF)-1alpha inhibitors. Bioorganic & Medicinal Chemistry Letters 20: 1453–1456.

    Article  CAS  Google Scholar 

  • Shweiki, D., A. Itin, D. Soffer, and E. Keshet. 1992. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359: 843–845.

    Article  CAS  PubMed  Google Scholar 

  • Spring, D.R. 2005. Chemical genetics to chemical genomics: small molecules offer big insights. Chemical Society Reviews 34: 472–482.

    Article  CAS  PubMed  Google Scholar 

  • Varrone, S., E. Consiglio, and I. Covelli. 1970. The nature of inhibition of mitochondrial malate dehydrogenase by thyroxine, iodine cyanide and molecular iodine. European Journal of Biochemistry 13: 305–312.

    Article  CAS  PubMed  Google Scholar 

  • Welsh, S., R. Williams, L. Kirkpatrick, G. Paine-Murrieta, and G. Powis. 2004. Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha. Molecular Cancer Therapeutics 3: 233–244.

    CAS  PubMed  Google Scholar 

  • Won, M.S., N.H. Im, S.H. Park, S.K. Boovanahalli, Y.L. Jin, X.J. Jin, K.S. Chung, M. Kang, K. Lee, S.K. Park, H.M. Kim, B.M. Kwon, J.J. Lee, and K. Lee. 2009. A novel benzimidazole analogue inhibits the hypoxia-inducible factor (HIF)-1 pathway. Biochemical and Biophysical Research Communications 385: 16–21.

    Article  CAS  PubMed  Google Scholar 

  • Xia, Y., M. Won, J.E. Kang, S.K. Park, K. Lee, H.M. Kim, and K. Lee. 2010. Synthesis and biological evaluation of 2-aminoisonicotinic acid analogues as HIF-1α inhibitors. Bulletin of the Korean Chemical Society 31: 3826–3829.

    Article  CAS  Google Scholar 

  • Xia, Y., Y. Jin, N. Kaur, Y. Choi, and K. Lee. 2011. HIF-1α inhibitors: Synthesis and biological evaluation of novel Moracin O and P analogues. European Journal of Medicinal Chemistry 46: 2386–2396.

    Article  CAS  PubMed  Google Scholar 

  • Xia, Y., H.K. Choi, and K. Lee. 2012. Recent advances in hypoxiainducible factor (HIF)-1 inhibitors. European Journal of Medicinal Chemistry 49: 24–40.

    Article  CAS  PubMed  Google Scholar 

  • Yeo, E.J., Y.S. Chun, Y.S. Cho, J. Kim, J.C. Lee, M.S. Kim, and J.W. Park. 2003. YC-1: A potential anticancer drug targeting hypoxia-inducible factor 1. Journal of the National Cancer Institute 95: 516–525.

    Article  CAS  PubMed  Google Scholar 

  • Ziegler, S., V. Pries, C. Hedberg, and H. Waldmann. 2013. Target identification for small bioactive molecules: Finding the needle in the haystack. Angewandte Chemie (International Edition in English) 52: 2744–2792.

    Article  CAS  Google Scholar 

Download references

Acknowledgments

This study was supported by National Research Foundation (NRF) Grants (2012M3A9C1053532 and 2014R1A2A2A01005455) funded by the Korean Government.

Author information

Authors and Affiliations

  1. BK21Plus R-FIND Team, College of Pharmacy, Dongguk University-Seoul, Goyang, 410-820, South Korea

    Ravi Naik, Seunghyeon Han & Kyeong Lee

Authors
  1. Ravi Naik
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Seunghyeon Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kyeong Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kyeong Lee.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Naik, R., Han, S. & Lee, K. Chemical biology approach for the development of hypoxia inducible factor (HIF) inhibitor LW6 as a potential anticancer agent. Arch. Pharm. Res. 38, 1563–1574 (2015). https://doi.org/10.1007/s12272-015-0632-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12272-015-0632-5

Keywords

Search

Navigation